IMC-003
Biologic (subtype unspecified)
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07593027 NCT07593027 · Pulmonary Arterial Hypertension PAH Registry: NCT07593027 | 1/2 | Phase Ib (24 weeks); Phase IIa (24 weeks) 2027-10-31 | In progress: results expected 31 Oct 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other Activin receptor type IIA (ActRIIA) drugs
Sotatercept, LAE102, HS235. Compare all 4 Activin receptor type IIA (ActRIIA) drugs
3 other tracked programmes target this mechanism, 2 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| IMC-003: this drug | Phase 1/2 | Biologic (subtype unspecified) | Activin receptor type IIA (ActRIIA) | not yet graded | No reviewed efficacy summary | |
| Sotatercept (Winrevair) | Approved(overall) | Protein / enzyme therapeutic | Activin receptor type IIA (ActRIIA) | Reliable signal | NCT04576988: Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24 (Baseline and Week 24): Sotatercept Plus Background PAH Therapy (DBPC Period) 34.4 meters (range 32.5 to 35.5) vs Placebo Plus Background PAH Therapy (DBPC Period) 1 meters (range -1 to 5) NCT04896008: First death, lung transplantation or PAH-worsening hospitalization: sotatercept 17.4% (15/86) vs placebo 54.7% (47/86), HR 0.24 (95% CI 0.13 to 0.43), P<0.001; trial stopped early for efficacy (ZENITH, NEJM 2025). | |
| LAE102 | Phase 2(overall) | Monoclonal antibody | Activin receptor type IIA (ActRIIA) | not yet graded | No reviewed efficacy summary | |
| HS235 | Phase 1/2(overall) | Peptide | Activin receptor type IIA (ActRIIA) | Weak signal | No reviewed efficacy summary |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow IMC-003 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.